RELA and STAT5 proteins transcriptionally activate the expression of Bcl-xL through direct promoter binding in ovarian, non-small-cell lung carcinoma and transformed leukemia cells, as well as render chemoresistance in carboplatin resistant ovarian cancer cell lines [19,54,55]. Here, BCL2L1 is linked to ovarian cancer.